Back to search

Article

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

2022-12-06

Abstract excerpt

<h4>Background</h4> COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. <h4>Methods</h4> We conducted a global Phase 3, multi-stage efficacy study ( NCT04904549 ) among adults aged ≥18 years. Participants were randomized 1:1 to receive two intramuscular injections 21 days apart of a bivalent SARS-CoV-2 recombinant p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3369b36e-df5b-5c26-af0a-ad1778ef524e
DOI
10.1101/2022.12.05.22282933
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineDOI 10.1101/2022.12.05.22282933
Select a neighboring publication to make it the new centre.